Peculiarities of carbohydrate metabolism in patients with comorbid course of type 2 diabetes mellitus: Relationship with IRS1 gene polymorphism

  • Received 15.12.2020

  • Revised 27.01.2021

  • Accepted 23.02.2021



  • 910 Views

  • Retrieved from Volume 3, No. 1, 2021

  • Pages 37-45

Summary. Despite significant advances in genetic predisposition to type 2 diabetes mellitus (T2DM), which have been confirmed by large-scale genomic and clinical studies, most of the genetic factors that cause the development of T2DM remain unclear. The aim of the study – to determine the association of IRS1 gene polymorphism (rs2943640) with carbohydrate metabolism in patients with type 2 diabetes mellitus in combination with obesity and chronic pancreatitis. Materials and Methods. The study included 33 patients with T2DM (patients with T2DM, T2DM + obesity, T2DM + obesity + chronic pancreatitis) and 10 healthy individuals. The level of glycated hemoglobin (HbA1c) was determined using an automatic biochemical analyzer COBAS 6000 (Roche Hitachi, Germany). The level of insulin in the blood was determined on an enzyme-linked immunosorbent assay from Thermo Scientific Multiskan FC, and the glucose concentration was determined using standard kits on an automatic biochemical analyzer from COBAS INTEGRA® 400 (Roche Diagnostics). Polymorphism of the IRS1 gene (rs2943640) C> A was genotyped by real-time PCR TaqMan method (Applied Biosystems, Foster City, CA, USA). Results. Carriers of the C allele of the IRS1 gene (rs2943640), patients with combined type 2 diabetes, obesity and chronic pancreatitis have the highest levels of insulin and HOMA-IR, which are probably higher than in patients with type 2 diabetes (329.75 %, respectively) and 65.13 %) and in patients with combined type 2 diabetes and obesity (314.53 % and 69.23 %, respectively). Patients with type 2 diabetes mellitus, regardless of the presence/absence of comorbid obesity and chronic pancreatitis, carriers of the C/C genotype of the IRS1 gene (rs2943640) have the highest carbohydrate metabolism, relative to the data of carriers of the C/A genotype. Conclusions. In patients with combined course of type 2 diabetes, obesity and chronic pancreatitis, the nature of carbohydrate metabolism disorders is influenced by polymorphism of the IRS1 gene (rs2943640)

type 2 diabetes mellitus; obesity; chronic pancreatitis; comorbidity; IRS1 gene; allele; genotype; carbohydrate metabolism

https://doi.org/10.11603/bmbr.2706-6290.2021.1.12102

[1] Zheng  Y,  Ley  SH,  Frank  BH.  Global  aetiology and  epidemiology  of  type  2  diabetes  mellitus  and  its complications. Nat. Rev. Endocrinol. 2018;14(2): 88-98.

[2] Kaiser A, Zhang N, Der Pluijm WV. Global prevalence of type 2 diabetes over the next ten years (2018–2028). Diabetes. 2018;67(1): 202-LB.

[3] International  Diabetes  Federation.  IDF  Diabetes Atlas  9th  edition  2019.  International  Diabetes  Federation [Internet]. [cited 2020 Aug 21]. Available from: https://www.idf.org/aboutdiabetes/what-is-diabetes/facts-figures.html.

[4] Blüher  M,  Stumvoll  M.  Diabetes  and  Obesity.  In: Bonora  E.,  De  Fronzo  R.  (eds)  Diabetes  Complications, Comorbidities  and  Related  Disorders.  Endocrinology. Springer, Cham. 2018.

[5] Melikhova SP, Shevcova VI, Zujkova AA, Kotova JuA. [Studying of comorbid pathology at the 2 type s diabetes as the complication of the metabolic syndrome]. The Russian Archives of Internal Medicine. 2018;8(5): 366-71. Russian.

[6] Hosseini S, Alipour M, Zakerkish M, Cheraghian B, Ghandil  P.  Effects  of  epigallocatechin  gallate  on  total antioxidant  capacity,  biomarkers  of  systemic  low-grade inflammation  and  metabolic  risk  factors  in  patients  with type  2  diabetes  mellitus:  the  role  of  FTO-rs9939609 polymorphism. Archives of Medical Science. 2020.

[7] Saboor Aftab  SA,  Reddy  N,  Smith  E,  Barber TM. Obesity and Type 2 Diabetes Mellitus. Intern Med. 2014;S6: 002. DOI:10.4172/2165-8048.S6-002.

[8] Lin YK, Johnston PC, Arce K, Hatipoglu BA. Chronic pancreatitis  and  diabetes  mellitus.  Current  Treatment Options in Gastroenterology. 2015;13(3): 319-31.

[9] Hardt  PD,  Hauenschild A,  Nalop  J,  Marzeion AM, Jaeger C, Teichmann J, et al. High prevalence of exocrine pancreatic insufficiency in diabetes mellitus. A multicenter study  screening  fecal  elastase  1  concentrations  in  1,021 diabetic  patients.  Pancreatology.  2003;3(5):  395-402. Available from: https://doi.org/10.1159/000073655.

[10] Zhuravleva LV, Shekhovtsova YuA. Comorbidity of chronic pancreatitis and diabetes type 2: possible options of pharmacoteraphy. Practical likar. 2016;5(3): 21-5.

[11] Flannick  J,  Florez  JC.  Type  2  diabetes:  genetic data sharing to advance complex disease research. Nature Reviews Genetics. 2016;17(9): 535.

[12] Fuchsberger C, Flannick J, Teslovich TM , Mahajan A, Agarwala V, Gaulton KJ et al. The genetic architecture of type 2 diabetes. Nature. 2016; 536(7614): 41.

[13] Plengvidhya  N,  Chanprasert  C,  Chongjaroen  N, Yenchitsomanus  Pt,  Homsanit  M,  Tangjittipokin  W.  Impact of  KCNQ1,  CDKN2A/2B,  CDKAL1,  HHEX,  MTNR1B, SLC30A8, TCF7L2, and UBE2E2 on risk of developing type 2 diabetes in Thai population. BMC Med Genet. 2018;19: 93.

[14] Musiienko  VA,  Marushchak  MI.  [Type  2  diabetes and thyroid disease: Finding common mechanisms]. Visn med i biol dosl. 2020;1: 74-82. Ukrainian.

[15] Yiannakourisa N, Cooper JA, Shah S, Drenos F, Ireland  HA,  W.  Stephens  JW  et  al.  IRS1  gene  variants, dysglycaemic metabolic changes and type-2 diabetes risk. Nutr Metab Cardiovasc Dis. 2012;22(12): 1024-30.

[16] Yousef AA, Behiry EG, Allah WMA, Hussien AM, Abdelmoneam  AA,  Imam  MH,  et  al.  IRS-1  genetic polymorphism  (r.2963G>A)  in  type  2  diabetes  mellitus patients associated with insulin resistance. Appl Clin Genet. 2018;11: 99-106.

[17]  American  Diabetes  Association.  Standards  of Medical Care in Diabetes – 2019 abridged for primary care providers. Clin Diabetes. 2019;37(1): 11-34.

[18] Conwell  DL,  Lee  LS,  Yadav  D,  Longnecker  DS, Miller FH, Mortele KJ et al. American Pancreatic Association Practice  Guidelines  in  Chronic  Pancreatitis:  evidence-based  report  on  diagnostic  guidelines.  Pancreas.  2014; 43(8):  1143-62. Available  from: https://doi.org/10.1016/j.numecd.2011.05.009

[19] Roy S, Sherman A, Monari-Sparks MJ, Schweiker O, Jain N, Sims E et al. Association of Comorbid and Metabolic Factors with Optimal Control of Type 2 Diabetes Mellitus. N  Am  J  Med  Sci.  2016;8(1):  31-9.  DOI:  10.4103/1947-2714.175197. PMID: 27011945; PMCID: PMC4784181.

[20] Nowakowska  M,  Zghebi  SS,  Ashcroft  DM  The comorbidity  burden  of  type  2  diabetes  mellitus:  patterns, clusters and predictions from a large English primary care cohort. BMC Med.2019; 17:145. Available from: https://doi.org/10.1186/s12916-019-1373-y.

[21] Tirkes  T,  Jeon  CY,  Li  L,  Joon  AY,  Seltman  TA, Meghana  Sankar  M  et  al.  Association  of  pancreatic steatosis  with  chronic  pancreatitis,  obesity,  and  type 2  diabetes.  Pancreas.  2019;48(3):  420-6.  10.1097/MPA.0000000000001252

[22] Iribarren C, Karter AJ, Go AS, Ferrara A, Liu JY, Sidney S et al. Glycemic control and heart failure among adult  patients  with  diabetes.  Circulation.  2001;103(22): 2668-73.   Available   from:   https://doi.org/10.1161/01.CIR.103.22.2668

[23] Jabir M, Lang C. Glycaemic control & heart failure development in the diabetic patient. SUMJ. 2012;1: 63-75.

[24] Nichols  GA,  Hillier  TA,  Erbey  JR,  Brown  JB. Congestive  heart  failure  in  type  2  diabetes:  prevalence, incidence,  and  risk  factors.  Diabetes  Care.  2001;24(9): 1614-9.

[25] Yang Q, Graham TE, Mody N, Preitner F. Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Nature. 2005;436(7049): 356. DOI:  10.1038/nature03711.  [PubMed]  [CrossRef]  [Google Scholar]

[26] Muoio DM, Newgard CB. Molecular and metabolic mechanisms of insulin resistance and β-cell failure in type 2  diabetes.  Nat  Rev  Mol  Cell  Biol.  2008;9(3):  193-205. DOI:  10.1038/nrm23

[27] [PubMed]  [CrossRef]  [Google Scholar]27. Jakobsen SN, Hardie DG, Morrice N, Tornqvist HE. 5′-AMP-activated  protein  kinase  phosphorylates  IRS-1 on Ser-789 in mouse C2C12 myotubes in response to 5-aminoimidazole-4-carboxamide  riboside.  J  Biol  Chem. 2001;276(50): 46912-6. DOI: 10.1074/jbc.C100483200.

[28] Kilpelainen  TO,  Zillikens  MC,  Stancakova  A, Finucane FM, Ried JS, Langenberg C et al. Genetic variation near IRS1 associates with reduced adiposity and an impaired metabolic profile. Nat Genet. 2011;43(8): 753-60.

[29] Shu XO, Long J, Cai Q, Qi L, Xiang YB, Cho YS et al. Identification of new genetic risk variants for type 2 diabetes. PLoS Genet. 2010;6(9):e1001127. Available from: https://doi.org/10.1371/journal.pgen.1001127.

[30] Shalimova  AS.  Association  of  IRS>1  gene polymorphism  with  violations  of  blood  lipid  spectrum  in patients with essential hypertension and concomitant type 2 diabetes. FAMILY MEDICINE. 2015;3(59): 102-4.

[31] Minchenko  DO,  Davydov  VV,  Budreiko  OA, Moliavko  OS,  Kulieshova  DK,  Tiazhka  OV  et  al.  The expression  of  CСN2,  IQSEC,  RSPO1,  DNAJC15,  RIPK2, IL13RA2, IRS1, and IRS2 genes in blood of obese boys with insulin resistance. Physiology Journal. 2015;1(61): 10-8.

[32] Vassy JL, Hivert MF, Porneala B, Dauriz M, Jose C. Florez JC et al. Polygenic type 2 diabetes prediction at the limit of common variant detection. Diabetes. 2014;63: 2172-82 . DOI: 10.2337/db13-1663.

[33] Qi Q, Bray GA, Smith SR, HuFB, Sacks FM, Qi L. Insulin  receptor  substrate  1  gene  variation  modifies insulin resistance response toweight-loss diets in a 2year randomized trial: the Preventing Overweight Using Novel Dietary  Strategies  (POUNDS  LOST)  trial.  Circulation. 2011;124(5): 563-71.

[34] Samuel  VT,  Petersen  KF,  Shulman  GI.  Lipid-induced  insulin  resistance:  unravelling  the  mechanism. Lancet. 2010;375: 2267-77.